The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer in NRG/RTOG 1016

J. B. Weidhaas,J. Harris,M. Gillison,D. M. Blakaj, G. A. Krempl,K. A. Higgins,J. Phan,N. E. Dunlap,S. Mahmood, J. A. Dorth, J. J. Caudell, A. B. Desai,T. J. Galloway, J. D. D. Pennington, Z. Zhou, J. Lathrop,P. Torres-Saavedra, D. N. Hayes,S. S. Yom,Q. T. Le

International journal of radiation oncology, biology, physics（2023）

引用 0|浏览6

暂无评分

摘要

While this study does not directly refute prior evidence that KRAS-variant patients benefit from radiation + cisplatin and cetuximab, this study does not support the hypothesis that the KRAS-variant is a predictive biomarker of improved outcome in HPV+ oropharyngeal SCC patients treated with IMRT + cetuximab alone, and suggests that for KRAS-variant patients, potential benefits in LRF and acute toxicity with cetuximab may be offset by worse DM and worse late toxicity.

查看译文

关键词

cancer,cetuximab,kras-variant,hpv-positive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要